FDA Delays Ascendis Pharma’s Drug Review

Ascendis Pharma A/S (ASND) has released an update.

Ascendis Pharma A/S has announced a three-month delay by the FDA for the review of their New Drug Application for TransCon PTH, a treatment for adults with hypoparathyroidism, with a new target action date set for August 14, 2024. This extension is due to a major amendment submitted by the company, necessitating additional time for a thorough review.

For further insights into ASND stock, check out TipRanks’ Stock Analysis page.